Expert Forum Sponsored by Simcere Pharmaceuticals

Join us, if you are stronger! (CABA)

立即制作

發(fā)布者：先聲生物

發(fā)布時(shí)間：2017-09-05

版權(quán)說明：該作品由用戶自己創(chuàng)作，作品中涉及到的內(nèi)容、圖片、音樂、字體版權(quán)由作品發(fā)布者承擔(dān)。

侵權(quán)舉報(bào)

Join us, if you are stronger! (CABA)H5，H5頁面制作工具

Dr. Sommadossi is the Founder, Chairman and CEO of Atea Pharmaceuticals. Jean-Pierre has over 30 years of scientific, operational, strategic and management experience in the biotech industry. Previously Jean-Pierre was the Principal Founder of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and a Co-Founder of Pharmasset, Inc. (NASDAQ: VRUS). Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014 and Pharmasset by Gilead for $11 billion in 2012. Jean-Pierre held a number of key executive positions at Idenix, including Chairman of the Board of Directors, Executive President and Chief Scientific Officer from 1998 to 2000, and then as Chairman and Chief Executive Officer from 2000 to 2010.

He is a member of the Harvard Medical School Therapeutics Advisory Council and the Harvard Medical School Discovery Council, Chairman of the Board, Panchrest, Inc., Chairman of the Board of Kezar Life Sciences, Inc., a Member of the Board of The BioExec Institute and a Senior Advisor to PureTech Ventures, as well.

Prior to his entrepreneurial career, Jean-Pierre was on the faculty of the University of Alabama at Birmingham School of Medicine since March 1985. He served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology from June 1992 to November 2000.

He has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of cancer and infectious diseases. Jean-Pierre holds a Pharm. D. and Ph. D. in Pharmacology from the University of Marseilles, France and was a post doctoral Fogarty fellow at the National Cancer Institute and the Medical College of Virginia, and is a recipient of a Faculty Award from The American Cancer Society.

Dr. Gutiérrez-Ramos has over 20 years of drug discovery and development experience from leading global biopharmaceutical companies. He currently serves as Chief Executive Officer of Synlogic Inc. Previously, he served as Group Senior Vice President and global head of the BioTherapeutics Research at Pfizer where he was responsible for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He also oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing.

Before that, Dr. Gutiérrez-Ramos was Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc.) into therapeutics. Prior to his work in the pharmaceutical industry, Dr. Gutiérrez-Ramos held senior leadership positions at several biotech companies, including Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery.

During his academic career he was part of the Faculty at the Genetics Department of Harvard Medical School and the Basel Institute for Immunology in Switzerland. Dr. Gutiérrez-Ramos holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.

Meredith Fisher, PhD is a Partner at the Partners Innovation Fund- the venture arm of Partners Healthcare System in Boston, MA. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies.

Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development of Enlight Biosciences- a venture creation company founded by PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals (formerly, Scriptgen).

Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD in molecular microbiology from Harvard University.

Executive Vice President, Pharmaceuticals
Dr. Wang manages manufacturing, API sales, international regulatory affairs, and Simcere Europe. Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China. Dr. Wang was instrumental for the development and commercialization of Conbercept, a fusion protein approved in 2013 in China as the longest lasting wAMD drug in the world. As CEO, he led the company to achieve triple digit growth and transitioned the previously single product-centric company to a full-fledged biotech business covering integrated R&D of multiple products, commercial manufacturing & distribution, and international development.

In 2016, he successfully led his team to open a FDA IND for Conbercept to bypass Phases 1&2 and directly enter Phase 3 in the US, a rarity for novel biologics originally developed outside the US and the first for China. Prior to Kanghong Biotech, Dr. Wang worked at Genzyme in Cambridge, MA, where he led critical projects for a number of innovative products including MACI, the first tissue engineering product approved by the FDA for adult cartilage repair. While at Genzyme, Dr. Wang had two US/PCT patents and supported international marketing. Dr. Wang earned his Ph.D at Tufts University and had 10 peer reviewed publications with totally over 3000 citations.

Dr. Shuqi Chen, was the founder, CEO and Chairman of the Board of IQuum, Inc., which was acquired by Roche Molecular System. Inc., in 2014. After the merger, he severed as Vice President, Research and Development of Point of Care at Roche Molecular System for 2 years.

Dr. Chen's vision and innovative approach to medical diagnostics was the basis for the cobas? Liat system. He led IQuum to successfully develop the Liat technology and commercialize lab-quality POC molecular-diagnostic products prior to its acquisition by Roche. In recognition of his leadership at IQuum, Dr. Chen received the 2014 CEO Award from Finance Monthly. Further, in recognition of his leadership in the IQuum and Roche merger, he was awarded the Massachusetts’s Most Innovative Business Leaders of 2015 Awards from Acquisition International.

Prior to IQuum, Dr. Chen was a Faculty Member at Harvard Medical School. His research resulted in many papers published in prestige journals such as PNAS and Nature. He obtained a B.S. in Theoretical Physics, an M.S. in Biophysics, and a Ph.D. in Biology & Biophysics.

Guest professor, China Pharmaceutical University, Nanjing Medical University, Nanjing University of Chinese Medicine
Vice President, PhIRDA
1. Vice Chairman of Jiangsu Association for Science and Technology
Founder and Chairman
Simcere Pharmaceutical Group
Precision Med BioSciKin

22 years of industrial experiences with R&D, sales，marketing, etc. and a trained physician

An industry-wide reputation in growing the sales of a product by 7 times to 2 bn RMB when served as GM at Shihuida Pharma
President
Simcere Pharmaceutical Group

MBA from University of Chicago, Engineering bachelor's degree from Tongji University

Board member of Asian Investment Bank BU of Bank of America Merrill Lynch, global market financing and M&A

Credit Suisse

Deutsche Bank
Vice President
International BD

Ph.D. from Boston College, USA

20+ years of industrial experience in biological drug development at Pfizer, EMD Serono, J&J

Major contributor of discovery and develop of EMD Serono’s recently approved anti-PD-L1, and multiple IND preparation and patent filing
Executive Director
Translational Medicine, SBP

Ph.D. from Indiana University

Senior leadership positions in Guojian, Roche, BI, Covance

Reviewer of CFDA

Reviewer of National Key Innovative Drug R&D Projects
Executive Director
Head of Preclinical R&D

Ph.D. from University of Texas at Austin, USA

5 years’ Ab discovery, Principal Scientist at Xbiotech USA

2 years’ senior leadership at Wuxi AppTec

3 mAb drugs (1 NDA with EMA, 1 in Ph2 with FDA)
Executive Director
Head of Antibody Discovery

Ph.D. from University of Cambridge

18 years' experience in discovery & development at Eisai Europe, Sanofi, Takeda & GSK Singapore

Led 8 molecules to pre-clinical, 1 to clinical & 2 to market
Senior Director
Head of Discovery Biology & Pharmacology

Ph.D. from East China Science and Technology University

7 years' leadership in biologics development in Simcere

Major contributor of 2 INDs with CFDA
Director
Head of Protein Production

Click Here
Do you want to hear the Sovaldi story behind the scene from the Pharmasset co-founder?

Do you want to know how to cultivate multi-billion biotech company and get it public or sold?

Do you want to know the current landscape and trend of gene therapy and biotherapeutics?

Do you want to understand Chinese Pharma companies' ambition and strategy of life-science innovation?

If the answer is yes，please click the button for a complimentary registration.